Alopecia Areata
Conditions
Keywords
alopecia areata, betamethasone, latanoprost, topical steroid, prostaglandin
Brief summary
Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. The two agents have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.
Detailed description
Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. Topical prostaglandins like latanoprost have also been used for this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. However, the two agents i.e. topical corticosteroids and topical latanoprost have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.
Interventions
DRUGTopical latanoprost 0.005%
Local application of the drug on affected skin/scalp
Local application of the drug on affected skin/scalp
Sponsors
Post Graduate Institute of Medical Education and Research, Chandigarh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 99 Years
Healthy volunteers
No
Inclusion criteria
* • Cases of AA involving scalp and beard area, having 5 or less patches in all, involving less than 40% area * Stable disease without appearance of new patch or increase in size of existing patch for at least 15 days
Exclusion criteria
* • Pregnant and lactating women * Patients on topical treatment for alopecia in the past fifteen days or on systemic treatment for alopecia in the past one month * Presence of any contraindication for topical corticosteroids (local skin infections, skin atrophy) or latanoprost (pregnancy, lactation and dermatitis) * Any other coexisting hair disorder (viz., trichotillomania, androgenetic alopecia, telogen effluvium) * Extensive disease i.e. \>5 patches of AA or area involving \>40% area / alopecia totalis/ alopecia universalis/ ophiasis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with hair regrowth (complete, partial, or no regrowth) | 4 months | Response to the treatment in terms of hair regrowth will be assessed. The reduction in the area affected by alopecia areata will be assessed for each patient |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients suffering from adverse effects | 4 months | The adverse effects of the study drugs will be assessed including erythema, pruritus, skin atrophy, dermatitis, telangiectasia, and others |
Countries
India
Outcome results
None listed